NCT04917315View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

May 21, 2020

Primary Completion Date

August 18, 2021

Study Completion Date

August 18, 2021

Conditions
Overactive Bladder
Interventions
DRUG

JLP-2002 A mg

administration of JLP-2002 Participants received one vibegron A mg tablet, taken orally each morning, for 12 weeks.

DRUG

Placebo

administration of Placebo Participants received one placebo tablet, taken orally each morning, for 12 weeks.

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Jeil Pharmaceutical Co., Ltd.

INDUSTRY

NCT04917315 - To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder | Biotech Hunter | Biotech Hunter